Company Overview

Novo Nordisk A/S is a global pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of medicines for chronic diseases. The company operates primarily within the pharmaceuticals and biotechnology industries, with a strong focus on diabetes care, obesity treatment, and rare disease therapies. Its core revenue drivers are injectable and oral therapies for diabetes and obesity, including GLP-1–based treatments, which account for the majority of sales.

Founded in 1923 in Denmark, Novo Nordisk evolved from early insulin production into one of the world’s largest diabetes-focused healthcare companies. Over time, it expanded into obesity care, growth hormone therapy, and treatments for rare blood and endocrine disorders. The company is widely recognized for its scientific expertise in metabolic diseases, large-scale biologics manufacturing capabilities, and long-term commitment to research-driven innovation. Public listings exist in Denmark and via American Depositary Receipts in the United States; however, public filings consistently reference the NVO ADR ticker, while the NVON designation is not consistently supported across major regulatory or exchange records, and data is inconclusive based on available public sources.

Business Operations

Novo Nordisk organizes its activities around major operating segments focused on Diabetes and Obesity Care, Rare Disease, and Other Therapeutic Areas. The Diabetes and Obesity Care segment represents the dominant share of revenue and includes insulin products, GLP-1 receptor agonists, and combination therapies. The Rare Disease segment focuses on treatments for hemophilia, growth hormone disorders, and other rare endocrine conditions. Revenue is generated through direct product sales to healthcare systems, hospitals, pharmacies, and distributors globally.

Operations are fully integrated, spanning research and development, manufacturing, and global commercialization. Novo Nordisk controls proprietary biologics manufacturing facilities and delivery-device technologies. The company operates through wholly owned subsidiaries in major markets and maintains long-standing commercial partnerships for distribution and clinical development in certain regions, while retaining centralized control over product development and strategic decision-making.

Strategic Position & Investments

Strategically, Novo Nordisk prioritizes leadership in metabolic and chronic disease care, with significant investment directed toward obesity, cardiometabolic health, and next-generation biologic therapies. Growth initiatives include expanding manufacturing capacity for injectable therapies, advancing late-stage clinical pipelines, and pursuing lifecycle management of existing products through new indications and formulations.

The company has completed targeted acquisitions and licensing agreements to strengthen capabilities in drug delivery technologies, data-driven clinical development, and early-stage research platforms. Notable subsidiaries include Novo Nordisk Limited, Novo Nordisk Inc., and Novo Nordisk Pharma A/S, which support regional operations and specialized functions. Novo Nordisk is also actively investing in emerging therapeutic modalities and digital health tools that support patient adherence and real-world outcomes, while maintaining a disciplined capital allocation approach.

Geographic Footprint

Novo Nordisk is headquartered in Denmark and maintains a substantial global presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The United States is its single largest market by revenue, particularly for diabetes and obesity products, followed by key European and Asian markets.

Manufacturing facilities are located in Denmark, the United States, France, China, and Brazil, supporting both regional supply and global exports. Research and development centers operate primarily in Denmark, with additional R&D and clinical operations distributed internationally. Through subsidiaries and affiliates, the company markets products in more than 170 countries, reflecting significant international operational and investment influence.

Leadership & Governance

Novo Nordisk follows a long-term governance model anchored by the Novo Nordisk Foundation, which maintains controlling ownership and emphasizes sustainable value creation, scientific excellence, and societal impact. Leadership strategy focuses on patient-centric innovation, ethical business conduct, and long-term investment horizons rather than short-term earnings optimization.

Key executives include:

• Lars Fruergaard Jørgensen – President and Chief Executive Officer
• Karsten Munk Knudsen – Executive Vice President and Chief Financial Officer
• Marcus Schindler – Executive Vice President and Chief Scientific Officer
• Maziar Mike Doustdar – Executive Vice President, International Operations
• Dave Moore – Executive Vice President, U.S. Operations

The leadership team emphasizes disciplined execution, global access to medicines, and sustained investment in research and manufacturing capabilities to reinforce Novo Nordisk’s competitive position in chronic disease treatment.